Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069169 | 1.00 | USP2 (0.61) | USP2HTTLPAR5LPAR1LPAR3 | |
| SCHEMBL2070284 | 0.98 | USP2 (0.63) | USP2HTTLPAR5LPAR1LPAR3 | |
| SCHEMBL9813378 | 0.92 | USP2 (0.67) | USP2HTTLPAR5LPAR1LPAR3 | |
| SCHEMBL9813387 | 0.91 | USP2 (0.69) | USP2HTTLPAR5LPAR1LPAR3 | |
| SCHEMBL9813398 | 0.88 | USP2 (0.69) | USP2HTTLPAR5LPAR1LPAR3 | |
| SCHEMBL2069023 | 0.88 | USP2 (0.59) | USP2HTTLPAR5LPAR1LPAR3 | |
| SCHEMBL10072130 | 0.87 | USP2 (0.61) | USP2HTTLPAR5LPAR1LPAR3 | |
| SCHEMBL10071648 | 0.87 | USP2 (0.61) | USP2HTTLPAR5LPAR1LPAR3 | |
| SCHEMBL27347105 | 0.87 | USP2 (0.73) | USP2HTTLPAR5LPAR1LPAR3 | |
| SCHEMBL9813411 | 0.86 | USP2 (0.71) | USP2HTTLPAR5LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163939-B2 | Ascorbic acid derivative or salt thereof, production method thereof, and cosmetic | Seikwa Kasei Company, Limited (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110059034-A1 | ASCORBIC ACID DERIVATIVE OR SALT THEREOF, PRODUCTION METHOD THEREOF, AND COSMETIC | SEIWA KASEI COMPANY, LIMITED (JP) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059034-A1 | ASCORBIC ACID DERIVATIVE OR SALT THEREOF, PRODUCTION METHOD THEREOF, AND COSMETIC | CYP2R1, CYP24A1, RARA | USP2 2360/4885HTT 1304/4885LPAR5 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.